Tandem Diabetes Care (Tandem Diabetes Care) COGS-to-Revenue

: 0.53 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

Tandem Diabetes Care's Cost of Goods Sold for the three months ended in Dec. 2023 was $103.5 Mil. Its Revenue for the three months ended in Dec. 2023 was $196.8 Mil.

Tandem Diabetes Care's COGS to Revenue for the three months ended in Dec. 2023 was 0.53.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Tandem Diabetes Care's Gross Margin % for the three months ended in Dec. 2023 was 47.41%.

Tandem Diabetes Care COGS-to-Revenue Historical Data

The historical data trend for Tandem Diabetes Care's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tandem Diabetes Care Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

0.46

0.48

0.46

0.48

0.51

Tandem Diabetes Care Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue																0.48	0.51	0.48	0.52	0.53

Tandem Diabetes Care COGS-to-Revenue Calculation

Tandem Diabetes Care's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	380.028	/	747.718
	=	0.51

Tandem Diabetes Care's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	103.501	/	196.796
	=	0.53

Tandem Diabetes Care (NAS:TNDM) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Tandem Diabetes Care's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	103.501 / 196.796
	=	47.41 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Tandem Diabetes Care COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Tandem Diabetes Care's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Tandem Diabetes Care (Tandem Diabetes Care) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tandem Diabetes Care Inc (NAS:TNDM) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

TD5A:Germany

Address

11075 Roselle Street, San Diego, CA, USA, 92121

Website

https://www.tandemdiabetes.com

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. Nearly three quarters of total revenue is derived from the U.S., with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Executives

Dick Allen	director	11045 ROSELLE STREET, SAN DIEGO CA 92121
Shannon Marie Hansen	officer: SVP & General Counsel	C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Leigh Vosseller	officer: Senior Vice President and CFO	C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Kathleen Mcgroddy-goetz	director	C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Peyton R Howell	director	C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
David B Berger	officer: GENERAL COUNSEL	11045 ROSELLE STREET, SAN DIEGO CA 92121
Malagueira Joao Paulo Falcao	director	C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Myoungil Cha	director	C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Kim D Blickenstaff	director, officer: PRESIDENT AND CEO	C/O MEDIVATION, INC., 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94105
John F Sheridan	officer: EXECUTIVE VP AND COO	C/O TANDEM DIABETES CARE, INC., 11045 ROSELLE STREET, SAN DIEGO CA 92121
Christopher J Twomey	director	4767 NEXUS CENTRE DRIVE, SAN DIEGO CA 92121
Rebecca B Robertson	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
James Leal	officer: SVP, Operations	C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Elizabeth Anne Gasser	officer: EVP, Chief Strategy Officer	C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Susan Morrison	officer: CAO	11045 ROSELLE STREET, SAN DIEGO CA 92121